%0 Journal Article
%T Lectins in oncology and virology: Mechanisms of anticancer activity and SARS-CoV-2 inhibition.
%A Boliukh I
%A Rombel-Bryzek A
%A Bułdak RJ
%J Int J Biol Macromol
%V 275
%N 0
%D 2024 Aug 4
%M 38969035
%F 8.025
%R 10.1016/j.ijbiomac.2024.133664
%X Lectins are proteins or glycoproteins of non-immune origin with carbohydrate-binding properties. They are found both prokaryotic and eukaryotic organisms. The most abundant source of the lectins are plants. Many lectins have anticancer effects by directly exerting cytotoxic effects on malignant cells or indirectly activating the immune system. Lectins also have antiviral activities. These proteins can recognise glycoproteins on the surface of enveloped viruses and bind to them. This creates a physical barrier between them and the corresponding receptors on the surface of the host cell, which prevents the virus from entering the cell and can thus effectively inhibit the replication of the virus. In this review, we focus on the anticancer activities of selected lectins and the underlying mechanisms. We also discuss different types of lectins with antiviral activity. We have paid special attention to lectins with inhibitory activity against SARS-CoV-2. Finally, we outline the challenges of using lectins in therapy and suggest future research directions.